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Adenomyosis of the uterus is deﬁned as the presence of endometrial tissue, including glands and stroma,
situated at least 2.5 mm below the endometrialemyometrial junction and widely distributed within the
myometrium layer of the uterus. There is no consensus on the appropriate treatment for symptomatic
uterine adenomyosis in women who want to preserve their uterus, partly because adenomyosis is
somewhat enigmatic in diagnosis and owing to its clinical signiﬁcance. Hysterectomy, through either
exploratory laparotomy or minimally invasive procedures, is a deﬁnite treatment for uterine adeno-
myosis, once the women have completed childbirth or do not require future fertility. However, many
women with a uterine pathology still have a strong desire to preserve the uterus, for which conservative
and uterine-sparing procedures are increasingly used, and with which fertility preservation or quality-of-
life improvement can be achieved. Although medical management can be effective, similar to the
management of uterine ﬁbroids (myoma), its effect is often transient and rapid regrowth of adenomyosis
and relapse of symptoms and signs always occur once the treatment is stopped. Therefore, other stra-
tegies should be selected. Conservative and uterine-sparing surgery might be one of the most familiar
procedures of these uterine-sparing procedures. In this article, the latest knowledge and research evi-
dence on uterine-sparing surgery for uterine adenomyosis are reviewed.
Copyright  2014, Taiwan Association of Obstetrics & Gynecology. Published by Elsevier Taiwan LLC. All
rights reserved.f interest to declare.
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Adenomyosis was ﬁrst described in 1860 by von Rokitansky, who
foundahysterotropicoccurrenceof islandsof endometriumscattered
throughout the myometrium [1]. Frankl subsequently speciﬁed it as
adenomyosis interna in 1925 [2]. During the last decade, adeno-
myosis was identiﬁed as a downgrowth and invagination of the
endometrial basalis into the adjacentmyometriumafterdisruptionof
the normally intact boundary between them [3]. Adenomyosis is
characterized by the presence of heterotopic endometrial glands and
stromawithin themyometrium, accompaniedwith a variable degreeby Elsevier Taiwan LLC. All rights reserved.
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causes globular and cystic enlargement of the myometrium, with
some cysts ﬁlled with extravasated, hemolyzed red blood cells and
siderophages in gross appearance. In adenomyosis, the ectopic
endometrium is located past the “last” glands of the basalis, and cir-
cumferentially surrounded by bundles of hypertrophic smooth
muscle cells (collar), which clearly differ cytologically from stromal
ﬁbroblasts, and foci of adenomyosis (proliferative types of ade-
nomyotic glands and stroma) seen more than 2.5 mm deep in the
myometrium or more than one microscopic ﬁeld at 10 magniﬁca-
tion from the endometriumemyometrium junction [5]. The diag-
nosis relies on clinical manifestations, with themost frequently cited
proﬁle composed of the triad of abnormal uterine bleeding (50%),
secondary dysmenorrhea (30%), and an enlarged, tender uterus [6],
sometimes accompanied with subfertility [7,8].
The transabdominal ultrasound (TAS) characteristics include a
honeycomb pattern, sonolucent 5e7 mm spaces, myometrial cysts,
wide posterior wall, eccentric endometrial cavity, diffuse uterine
enlargement but with no leiomyomas, and diminished uterine
echogenicity [9e14]. However, the preoperative diagnosis of ade-
nomyosis cannot be reliably differentiated from that of leiomyoma
on TAS [9]. The transvaginal ultrasound (TVS) ﬁndings include
uterine enlargement not explainable by the presence of leiomyo-
mas, asymmetry (asymmetrical thickening of the anterior or pos-
terior uterine wall), lack of contour abnormality or mass effect,
retroversion, globular or spherical shape, and uterosacral ligament
nodularity for uterine body examination; focal honeycomb, scat-
tered, irregular, cystic, anechoic lacunae, heterogeneous increased
or decreased myometrial echoes, mottled texture, lesions sur-
rounded by anechoic shadows 1e3 mm in diameter, hyper-
echogenic or hypoechogenic striations, indistinct margins,
nonencapsulated myometrial lesion, and myometrial linear stria-
tion in the myometrium examination; and a shaggy endometrial
stripe, blurred endometrialemyometrial border, and thickened or
distorted endometrium in the endometrial examination. Although
these features are commonly imaged in women with adenomyosis,
there is no general agreement onwhich diagnostic criteria have the
highest diagnostic accuracy. According to Kepkep et al, the pres-
ence of subendometrial echogenic linear striations might be the
most speciﬁc ﬁnding for the diagnosis of uterine adenomyosis [10].
The presence of subendometrial echogenic linear striations, a het-
erogeneous myometrial echotexture, and myometrial anteriore
posterior asymmetry on TVS supports the diagnosis of adeno-
myosis [11]. A recent systematic review and meta-analysis showed
that TVS is a moderately accurate test for the diagnosis of adeno-
myosis, but as a preoperative test with ease of use, cost effective-
ness, and wide availability, it likely represents the most practical
diagnostic test for adenomyosis [9].
Magnetic resonance imaging (MRI) ﬁndings [12,13,15,16] may be
more helpful than TVS in distinguishing adenomyosis from a leio-
myoma and more effective for both diffuse and focal adenomyosis,
with sensitivity and speciﬁcity that are comparable with or even
better than those of ultrasound, as it depicts contrasts between
low-intensity lesions and surrounding tissues; however, it is more
expensive. The characteristic ﬁndings of MRI in uterine adeno-
myosis are a minimumwidth at the junction zone of 5 or 12 mm, a
focal and uneven width of the junction zone, low intensity of the
junction zone, high-intensity spots scattered within the junction
zone, and indistinct junction zone margins for the myometrial ex-
amination. From the histological perspective, areas of low-signal
intensity correspond to smooth muscle hyperplasia, and bright
foci on T2-weighted images correspond to islands of ectopic
endometrial tissue and cystic dilatation of glands [16]. When
menstrual hemorrhage occurs within these ectopic endometrial
tissues, signal intensity on T1-weighted images may become high.Challenge in the management of adenomyosis
Because the deﬁnite diagnosis of adenomyosis is based on a his-
tological examination, usually on a hysterectomy specimen [17],
adenomyosis is a neglected diagnosis [18]. Hysterectomy remains a
most important therapeutic option for women with symptomatic
adenomyosis [9], although medical management can be effective
[19e26], similar to the management of uterine ﬁbroids (myoma)
[26e34]. However, its effect is often transient and it is frequently used
with a preoperative adjuvant therapy or sometimes a postoperative
therapy [35e37]. Rapid regrowth of adenomyosis and relapse of
symptoms and signs always occurs after the treatment is stopped
[38]. Therefore, other alternative strategiesmight be needed. Surgery
might beoneof themost familiar of these uterine-sparingprocedures
[38e45]. The following sections summarize recently advanced
technologies and the outcomes of patients with adenomyosis and/or
adenomyoma after uterine-sparing surgical treatment.
Surgical treatment
Compared with the well-accepted gonadotropin-releasing hor-
mone agonist as a choice in themanagement of symptomaticwomen
with extensive adenomyosis who want to preserve their uterus,
conservative uterine-sparing surgery is seldomconsidered as playing
a role inmanaging these patients, partly because there is difﬁculty in
selecting a good candidate to undergo this surgical approach, and
partly because it is not easy to determine the extent of the adeno-
myosis involved and how much of the tumor should be removed.
Another consideration, based on the characteristics of the disease
itself (heterotopic endometrial glands and stroma widely spreading
and scattering throughout the myometrium, with adenomyosis foci
frequently mixing with the surrounding normal myometrium), was
that it is nearly impossible to complete resection of uterine adeno-
myosis using conservative uterine-sparing surgery. In addition, the
uterine cavity is frequently entered during the operation. One study
showed that nearly 30% of patients needed careful repair of the
uterine cavity during the tumor resection of adenomyosis [38].
Otherwise, it is more difﬁcult to repair the uterine defect after con-
servative uterine-sparing surgery for adenomyosis than for leio-
myoma [46], resulting in poor healing of the uterine defect or
weakness of the uterine scar after surgery. The uterine scars after
conservative uterine-sparing surgery of adenomyosis might not re-
turn tonormal tensile strength, partly because thedefectmaycontain
and conceal more adenomyotic foci and partly because repair is
neither adequate nor secure enough. The decreased tensile strength
of the uterus might also fail to be competent enough for future
pregnancy, because the ability of the uterus to enlarge and distend
alongwith an advanced-stage pregnancywas impaired, resulting in a
signiﬁcantly increased riskof a ruptureduterusduringpregnancyand
labor [47]. Because a similar risk has been reported in many patients
with a history of myomectomy [48,49], it is reasonable to expect a
much greater possibility of uterine rupture in these women after
conservative uterine-sparing surgery for adenomyosis when they are
pregnant. Besides theaforementionedconsiderations, there aremany
potential risks or possible sequelae following uterine-sparing sur-
gery, such as pelvic adhesion, uterine deformities, intrauterine ad-
hesions, and reduced uterine capacity. Therefore, the decision to use
conservative uterine-sparing surgery in the management of women
with extensive adenomyosis should be taken carefully.
Classiﬁcation of conservative uterine-sparing surgery for
adenomyosis
An excellent review addressing uterus-sparing operative treat-
ment for adenomyosiswas published online in November 2013 [3]. A
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surgical techniques for adenomyosis, classiﬁcation can be made
based on the extent of removal of adjacent healthy myometrium
and the preservation of the integrity and possible function of the
uterus [3]: this includes type Idcomplete and total eradication of
adenomyosis; and type IIdcytoreductive surgery of adenomyosis.
Type I can be exempliﬁed by adenomyomectomy [50,51], because
these patients always present a focal-type (localized) adenomyosis,
which can be relatively easy to excise clinically, or visibly recog-
nizable nonmicroscopic adenomyosis lesions that are relatively
clearly separated from the surrounding normal myometrium
compared with diffuse-type adenomyosis [52]. Type II means the
use of a cytoreductive surgical strategydwhich is very similar to
the management of advanced ovarian cancers [53,54]dto remove
as much of the visible tumor as possible [55], as it is nearly
impossible to remove all adenomyotic foci in this type of surgery. In
addition, concomitant resection of a large amount of healthy
myometrium with destruction of functional myometrium cannot
be totally avoided. Therefore, an old conceptdthe more radical, the
more effectivedneeds a balanced risk-to-beneﬁt ratio [56,57]. For
type I conservative uterine-sparing surgery, uterine wall integrity
can be maintained. For type II, a defect in the uterine wall might be
present. In theory, the risk of a ruptured pregnant uterus in type II
uterine-sparing surgery may be much higher than the risk in type I.Surgical techniques
In the type I procedure, complete resection of adenomyosis (also
called adenomyomectomy), all myomectomy procedures [58e66]
can be applied, with the only difference that the margin between
tumor and normal myometrium might be not as clear as with
adenomyomectomy. The technique includes the following [3]: (1)
careful and thorough recognition of the adenomyotic foci and their
borders by inspection and/or palpation (possible only in explor-
atory laparotomy); (2) longitudinal incision of the uterine wall
along the lesion; (3) sharp and delicate dissection of the adeno-
myoma from the surrounding relatively healthy myometrium tis-
sue using diathermy (the bipolar coagulator system is preferred
[67,68]) or scissor or knife, and preservation of maximal residual
serosa or serosa-muscular layer; (4) closure and reconstruction of
the uterine cavity using 4-0 absorbable suture if the uterine cavity
was opened; (5) closure of the uterine wall with 1-0 absorbableTable 1
Classiﬁcation of conservative uterine-sparing surgery for adenomyosis.
Characteristics Type I Type II
Possible candidate a Focal-type (localized)
adenomyosis
Diffuse-type
adenomyosis
Extent of excision Complete and total
eradication of
adenomyosis
Cytoreductive surgery
of adenomyosis
Residual tumor
(in theory)
Complete resection Optimal or suboptimal
Surgical technique Easier Much more difﬁcult
The risk of entering
uterine cavity
Low High
The risk of destroying
functional myometrium
Low High
Maintenance of uterine
integrity
Always Probably or possibly
The risk of ruptured
pregnant uterus
Low Possibly high
Symptom control Good to excellent Acceptable to fair
Fertility preservation High Probably low
a Symptomatic women who want to preserve the uterus and cannot tolerate
long-term hormone suppression therapy.sutures layer by layer; (6) closure of the serosa layers with 4-0 or 5-
0 absorbable sutures, if possible; (7) use of a critical amount of ﬂuid
to irrigate thewound and deposition of a lot of normal salinewithin
the abdominal cavity [69,70], although copious peritoneal irriga-
tion with a 1:10,000 dilution of heparin-containing lactated
Ringer’s solution might be better than normal saline solution [71].
Laparoscopic adenomyomectomy has been successfully performed
by some groups with excellent outcomes [72,73]. Grimbizis and
colleagues commented that laparoscopy is feasible either for
ablation of the adenomyotic foci or for excision of adenomyomas,
and laparoscopic suturing presents nomore difﬁculty than suturing
alone after myomectomy [3].
The type II proceduredconservative cytoreductive uterine-
sparing surgerydis more complicated, and many modiﬁcations
are used in the procedure. Fujishita and colleagues used a trans-
verse H-incision technique to perform this procedure for adeno-
myosis [74]. The main components of the three interconnecting “H”
incision are (1) a vertical incision with a 5-mm resection of the
uterine serosaemyometrium layer and two transverse incisions
perpendicular to the vertical incision along the upper and lower
edges of the uterus, which extend down both to the right edge of
the uterus up to the line connecting the right corners of the upper
and lower transverse incisions and to the left edge of the uterus
connecting the left corners of the upper and lower transverse in-
cisions; (2) removal of slices of adenomyotic tissue by serial
resection; (3) performing repeated chromopertubation tests by
injecting indigo carmine solution (Daiichi-Seiyaku Co. Ltd., Tokyo,
Japan) during the operation to minimize the risk of entering the
uterine cavity; (4) avoiding tension to the sutured tissue closing the
defect to minimize the risk of hematoma; (5) preferred use of
antiadhesive material [74,75].
Another classic method used to ﬁnish uterine-sparing surgery
for adenomyosis is very similar to myomectomy, although resection
must be done piece by piece, with preservation of as much of the
adjacent normal myometrium as possible [3]. The laparoscopic
approach might be possible, although laparotomy is much more
feasible that the surgeon can palpate and recognize the adenomy-
otic lesions intraoperatively [3]. In addition, there is no doubt that
the technique might be more complicated because the disease has
invaded the myometrium, and suturing the remaining uterine
wedges after resection is difﬁcult [3]. However, a new type of
intracorporeal absorbable barbed suture (V-Loc, TM 90; Covidien,
Mansﬁeld, MA, USA) has been introduced in gynecologic surgery toTable 2
Summary of outcomes of women with adenomyosis and/or adenomyoma after
uterine-sparing surgery.
Authors [Reference] Treatment (number) Symptom control
(6e24 mo)
Wang et al [38] Type II Excellent
Wood [41] Type II (18) Good
Type I (25) Excellent to good
Fujishita et al [74] Type II (11) Good to Fair
Wang et al [45] Type I (2) Good
Liu et al [77] Type I (10) Excellent to good
Type II (16) Good
Morita et al [73] Type I (3) Excellent
Grimbizis et al [72] Type I (6) Excellent
Strizhakov and Davydov [66] Type I (8) Excellent to good
Wang et al [51] Type I (51) Excellent to good
Nishida et al [78] Type II (44) Excellent
Osada et al [79] Type II (104) Excellent
Symptom control: unsatisfactory (exacerbation or improvement less than 25%); fair
(improvement between 25% and 50%); good: (improvement between 50% and 75%);
excellent (improvement more than 75%); Type I: complete and total eradication of
adenomyosis; Type II: cytoreductive surgery of adenomyosis.
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obtained [76]. This advancement in laparoscopic suture technology
may expand opportunities for laparoscopic adenomyomectomy or
even cytoreductive surgery of adenomyosis.
Therapeutic effects
The effectiveness of conservative uterine-sparing surgery for
adenomyosis and/or adenomyoma is promising (Table 2)
[38,41,45,51,72e74,77e79]. The main problem secondary to uterine
adenomyosis is dysmenorrhea, which can be improved signiﬁ-
cantly, up to 80%. Menorrhagia was also improved in more than
two-thirds of patients after type I uterine-sparing surgery, and
nearly half of the patients had improvement in their symptoms
after type II uterine-sparing procedures. The pregnancy rate was
also acceptable or good, ranging from 47% in type II surgery to 61%
in type I surgery [3].
Conclusion
Because of the limited amount of data available, the use of
uterine-sparing surgery in the management of uterine adeno-
myosis and/or adenomyoma is still controversial. However, based
on the inﬂammatory effects from adenomyosis, two possible ther-
apeutic options can be envisaged, surgical normalization of the
altered anatomy or bypass of the unfavorable pelvic and/or
abdominal environment. The former needs surgical cytoreduction,
which may discontinue the permanent inﬂammatory trigger and
overcome the unfavorable effect of adenomyosis [80], thereby
contributing to supporting the efﬁcacy and feasibility in these pa-
tients after conservative uterine-sparing surgery. There is no doubt
that possible surgical and obstetrical risks may not be fully avoided
[81e83]. In addition, some studies showed that the beneﬁts of
uterine-sparing surgery for uterine adenomyosis have been
strengthened by the following medical treatment [3,44,50,51,84].
Therefore, future research is warranted.
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